Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma—A randomized phase II trial

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Cell Lung Carcinoma ◽

Conventional Dose ◽

Randomized Phase Ii ◽

Ifosfamide and Vinorelbine as First-Line Chemotherapy for Advanced Non-Small Cell Lung Carcinoma

American Journal of Clinical Oncology ◽

10.1097/00000421-199612000-00011 ◽

1996 ◽

Vol 19 (6) ◽

pp. 584-588 ◽

Cited By ~ 5

Author(s):

C. Vallejo ◽

A. Romero ◽

J. Perez ◽

M. Cuevas ◽

J. Lacava ◽

...

Keyword(s):

Lung Carcinoma ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Cell Lung Carcinoma ◽

P2-309: Prospective phase II trial of a combination of gemcitabine, cisplatin and UFT as first-line treatment in patients with advanced, unresectable, non-small cell lung carcinoma

Journal of Thoracic Oncology ◽

10.1097/01.jto.0000284017.52158.e7 ◽

2007 ◽

Vol 2 (8) ◽

pp. S695-S696

Author(s):

Yong Joo Min ◽

Su Jin Shin ◽

Hawk Kim ◽

Jong Joon Ann ◽

Yang-Jin Je-Gal ◽

...

Keyword(s):

Lung Carcinoma ◽

Phase Ii Trial ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Cell Lung Carcinoma ◽

Prospective Phase ◽

First Line Treatment

6577 POSTER Prospective phase II trial of a combination of gemcitabine, cisplatin and UFT as first-line treatment in patients with advanced, unresectable, non-small cell lung carcinoma

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(07)71405-2 ◽

2007 ◽

Vol 5 (4) ◽

pp. 381

Author(s):

S.J. Shin ◽

Y.J. Min ◽

J.H. Baek ◽

H. Kim ◽

J.J. Ann ◽

...

Keyword(s):

Lung Carcinoma ◽

Phase Ii Trial ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Cell Lung Carcinoma ◽

Prospective Phase ◽

First Line Treatment

Blood T cell diversity associated with the prognosis of advanced non‐small cell lung carcinoma treated with first‐line pemetrexed based chemotherapy

Thoracic Cancer ◽

10.1111/1759-7714.13771 ◽

2021 ◽

Author(s):

Li Qian ◽

Zhang Zhaohui ◽

Xu Yaping ◽

Liu Zhentian ◽

Liu Zhentao ◽

...

Keyword(s):

T Cell ◽

Lung Carcinoma ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Cell Lung Carcinoma ◽

Cell Diversity

1266P Initial results from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected first-line metastatic non-small cell lung carcinoma

Annals of Oncology ◽

10.1016/j.annonc.2020.08.1580 ◽

2020 ◽

Vol 31 ◽

pp. S818

Author(s):

M. Majem ◽

E. Felip ◽

B. Doger ◽

M. Akay ◽

E. Carcereny ◽

...

Keyword(s):

Phase Ii ◽

Lung Carcinoma ◽

Phase Ii Study ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Cell Lung Carcinoma ◽

Initial Results

Advanced lung cancer inflammation index as a predictor of response rate in first-line chemotherapy for metastatic non-small cell lung carcinoma patients

Annals of Oncology ◽

10.1093/annonc/mdx671.048 ◽

2017 ◽

Vol 28 ◽

pp. x141

Author(s):

S. Chompoonuch ◽

P. Pratyarattananon ◽

O. Sukreeyapongse ◽

C. Upachar

Keyword(s):

Lung Cancer ◽

Response Rate ◽

Small Cell ◽

Advanced Lung Cancer ◽

Small Cell Lung ◽

First Line ◽

Cell Lung Carcinoma ◽

Cancer Inflammation ◽

First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy

Journal for ImmunoTherapy of Cancer ◽

10.1186/s40425-019-0600-6 ◽

2019 ◽

Vol 7 (1) ◽

Cited By ~ 18

Author(s):

Yixin Zhou ◽

Zuan Lin ◽

Xuanye Zhang ◽

Chen Chen ◽

Hongyun Zhao ◽

...

Keyword(s):

Lung Carcinoma ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Cell Lung Carcinoma ◽

First Line Treatment

Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial

Annals of Oncology ◽

10.1093/annonc/mdz278 ◽

2019 ◽

Vol 30 (10) ◽

pp. 1613-1621 ◽

Cited By ~ 10

Author(s):

J.M. Weiss ◽

T. Csoszi ◽

M. Maglakelidze ◽

R.J. Hoyer ◽

J.T. Beck ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Phase Ib ◽

Randomized Phase Ii ◽

A retrospective analysis of safety and efficacy of weekly nab-paclitaxel as second-line chemotherapy in elderly patients with advanced squamous non-small-cell lung carcinoma

Clinical Interventions in Aging ◽

10.2147/cia.s97363 ◽

2016 ◽

pp. 167 ◽

Cited By ~ 1

Author(s):

Jinming Yu ◽

Feng Jin ◽

Hui Zhu ◽

Fang Shi ◽

Li Kong

Keyword(s):

Elderly Patients ◽

Retrospective Analysis ◽

Lung Carcinoma ◽

Small Cell ◽

Second Line ◽

Small Cell Lung ◽

Cell Lung Carcinoma ◽

Safety And Efficacy ◽

13P High neutrophils-to-lymphocyte ratio (NLR) predicts poor survival of high-PD-L1-expressing metastatic non-small cell lung carcinoma patients undergoing first-line immunotherapy with pembrolizumab

Annals of Oncology ◽

10.1016/j.annonc.2021.10.029 ◽

2021 ◽

Vol 32 ◽

pp. S1379

Author(s):

F.J. Romano ◽

C. Barbato ◽

D. Arundine ◽

F. Ambrosio ◽

R. Ronga ◽

...

Keyword(s):

Lung Carcinoma ◽

Small Cell ◽

Small Cell Lung ◽

Poor Survival ◽

First Line ◽

Cell Lung Carcinoma ◽

Lymphocyte Ratio